Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

Related Citations for PubMed (Select 23328091)

1.

Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.

Phillips E, Bartlett JA, Sanne I, Lederman MM, Hinkle J, Rousseau F, Dunn D, Pavlos R, James I, Mallal SA, Haas DW.

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):e55-7. doi: 10.1097/QAI.0b013e31827ca50f. No abstract available.

2.

Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.

Haas DW, Bartlett JA, Andersen JW, Sanne I, Wilkinson GR, Hinkle J, Rousseau F, Ingram CD, Shaw A, Lederman MM, Kim RB; Adult AIDS Clinical Trials Group.

Clin Infect Dis. 2006 Sep 15;43(6):783-6. Epub 2006 Aug 15.

3.

Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.

Ritchie MD, Haas DW, Motsinger AA, Donahue JP, Erdem H, Raffanti S, Rebeiro P, George AL, Kim RB, Haines JL, Sterling TR.

Clin Infect Dis. 2006 Sep 15;43(6):779-82. Epub 2006 Aug 15.

4.

Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.

Ciccacci C, Borgiani P, Ceffa S, Sirianni E, Marazzi MC, Altan AM, Paturzo G, Bramanti P, Novelli G, Palombi L.

Pharmacogenomics. 2010 Jan;11(1):23-31. doi: 10.2217/pgs.09.142.

PMID:
20017669
5.

Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa.

Chu KM, Boulle AM, Ford N, Goemaere E, Asselman V, Van Cutsem G.

PLoS One. 2010 Feb 17;5(2):e9183. doi: 10.1371/journal.pone.0009183.

6.

Pharmacogenetics of antiretrovirals.

Tozzi V.

Antiviral Res. 2010 Jan;85(1):190-200. doi: 10.1016/j.antiviral.2009.09.001. Epub 2009 Sep 8. Review.

PMID:
19744523
7.

Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial.

Gozalo C, Gérard L, Loiseau P, Morand-Joubert L, Peytavin G, Molina JM, Dellamonica P, Becquemont L, Aboulker JP, Launay O, Verstuyft C; ANRS 081 Study Group.

Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):513-20. doi: 10.1111/j.1742-7843.2011.00780.x. Epub 2011 Sep 6.

PMID:
21824325
8.

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.

Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, Wakeford C, Shaw A, Quinn J, Gish RG, Rousseau F.

J Infect Dis. 2005 Mar 15;191(6):825-9. Epub 2005 Feb 10.

9.

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, Carné X, Phillips A, Gatell JM.

AIDS. 2001 Jul 6;15(10):1261-8.

PMID:
11426070
10.

HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.

Chantarangsu S, Mushiroda T, Mahasirimongkol S, Kiertiburanakul S, Sungkanuparph S, Manosuthi W, Tantisiriwat W, Charoenyingwattana A, Sura T, Chantratita W, Nakamura Y.

Pharmacogenet Genomics. 2009 Feb;19(2):139-46. doi: 10.1097/FPC.0b013e32831d0faf.

PMID:
19104471
11.

HIV drug nevirapine (Viramune): risk of severe hepatotoxicity.

Wooltorton E.

CMAJ. 2004 Mar 30;170(7):1091. No abstract available.

12.

Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.

Peters PJ, Stringer J, McConnell MS, Kiarie J, Ratanasuwan W, Intalapaporn P, Potter D, Mutsotso W, Zulu I, Borkowf CB, Bolu O, Brooks JT, Weidle PJ.

HIV Med. 2010 Nov;11(10):650-60. doi: 10.1111/j.1468-1293.2010.00873.x.

PMID:
20659176
13.

Nevirapine-induced hepatitis: a case series and review of the literature.

Piliero PJ, Purdy B.

AIDS Read. 2001 Jul;11(7):379-82. Review.

PMID:
11494710
14.

Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.

De Maat MM, Mathôt RA, Veldkamp AI, Huitma AD, Mulder JW, Meenhorst PL, Van Gorp EC, Carlier H, Beijnen JH.

Pharmacol Res. 2002 Sep;46(3):295-300.

PMID:
12220974
15.

Pharmacogenetic screening: HLA-B(*) 5701 vs. CYP2B6 G516T.

Lin AW, Yam WC, Lam HY, To S, Chan D, Chan KC, Lee SS.

HIV Med. 2011 Apr;12(4):255-6. doi: 10.1111/j.1468-1293.2010.00870.x. No abstract available.

PMID:
21371238
16.

Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.

Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro RM, Kityo C, Formentini E, Masur H.

HIV Med. 2007 Mar;8(2):86-91.

PMID:
17352764
17.

Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors.

Rivero A, Mira JA, Pineda JA.

J Antimicrob Chemother. 2007 Mar;59(3):342-6. Epub 2007 Jan 25. Review.

18.

Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.

De Requena DG, Jiménez-Nácher I, Soriano V.

AIDS Res Hum Retroviruses. 2005 Jun;21(6):555-9.

PMID:
15989460
19.

The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted.

Zhang C, Wang W, Zhou M, Han Y, Xie J, Qiu Z, Guo F, Li Y, Wang H, Ghanem KG, Li T.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):540-5. doi: 10.1097/QAI.0b013e3182845cc7.

PMID:
23288032
20.

Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.

Palmon R, Koo BC, Shoultz DA, Dieterich DT.

J Acquir Immune Defic Syndr. 2002 Apr 1;29(4):340-5.

PMID:
11917237
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk